Skip to main content

REVIEW article

Front. Med.
Sec. Ophthalmology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1497750
This article is part of the Research Topic Early-stage retinal diseases: Pathophysiology, Diagnostics and Therapeutics View all articles

Shared Signaling Pathways and Comprehensive Therapeutic Approaches Among Diabetes Complications

Provisionally accepted
Moein Ebrahimi Moein Ebrahimi 1Hamid Ahmadieh Hamid Ahmadieh 1Mozhgan Rezaei-Kanavi Mozhgan Rezaei-Kanavi 1Sare Safi Sare Safi 1Saeed Alipour-Parsa Saeed Alipour-Parsa 1Soroor Advani Soroor Advani 1Christine Sorenson Christine Sorenson 2Nader Sheibani Nader Sheibani 2*
  • 1 Shahid Beheshti University of Medical Sciences, Tehran, Tehran, Iran
  • 2 School of Medicine and Public Health, University of Wisconsin-Madison, Madison, United States

The final, formatted version of the article will be published soon.

    The growing global prevalence of diabetes mellitus (DM), along with its associated complications, continues to rise. When clinically detected most DM complications are irreversible. It is therefore crucial to detect and address these complications early and systematically in order to improve patient care and outcomes. The current clinical practice often prioritizes DM complications by addressing one complication while overlooking others that could occur. It is proposed that the commonly targeted cell types including vascular cells, immune cells, glial cells, and fibroblasts that mediate DM complications, might share early responses to diabetes. In addition, the impact of one complication could be influenced by other complications. Recognizing and focusing on the shared early responses among DM complications, and the impacted cellular constituents, will allow to simultaneously address all DM-related complications and limit adverse treatment impacts. This review explores the current understanding of shared pathological signaling mechanisms among DM complications and recognizes new concepts that will benefit from further investigation in both basic and clinical settings. The ultimate goal is to develop more comprehensive treatment strategies, which effectively impact DM complications in multiple organs and improve patient care and outcomes.

    Keywords: Diabetic Retinopathy, diabetic nephropathy, Diabetic neuropathy, Diabetic cardiomyopathy, Signal Transduction, Therapeutic targeting, metabolic dysregulation

    Received: 17 Sep 2024; Accepted: 23 Dec 2024.

    Copyright: © 2024 Ebrahimi, Ahmadieh, Rezaei-Kanavi, Safi, Alipour-Parsa, Advani, Sorenson and Sheibani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Nader Sheibani, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.